These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 25941160

  • 61. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE.
    Clin Ther; 2014 Aug 01; 36(8):1130-46. PubMed ID: 25015594
    [Abstract] [Full Text] [Related]

  • 64. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
    Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.
    Diabetes Obes Metab; 2015 Feb 01; 17(2):136-44. PubMed ID: 25298165
    [Abstract] [Full Text] [Related]

  • 65. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J, Pegelow K, Bramlage P.
    Vasc Health Risk Manag; 2013 Feb 01; 9():711-7. PubMed ID: 24259985
    [Abstract] [Full Text] [Related]

  • 66. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J, Kountz DS, Crowe S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2015 Jun 01; 127(5):419-28. PubMed ID: 25840727
    [Abstract] [Full Text] [Related]

  • 67. The MARLINA-T2D trial: putting the results into clinical perspective.
    Lajara R.
    Expert Rev Endocrinol Metab; 2018 May 01; 13(3):173-176. PubMed ID: 30058901
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct 01; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 70. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS.
    Diabetes Obes Metab; 2019 Apr 01; 21(4):781-790. PubMed ID: 30393950
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR.
    J Diabetes; 2017 Jul 01; 9(7):667-676. PubMed ID: 27502307
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial.
    Nauck MA, di Domenico M, Patel S, Kobe M, Toorawa R, Woerle HJ.
    Diab Vasc Dis Res; 2016 Jul 01; 13(4):286-98. PubMed ID: 27190087
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S, Patel S, Crowe S, von Eynatten M.
    Nutr Metab Cardiovasc Dis; 2016 Oct 01; 26(10):886-92. PubMed ID: 27484756
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.